PDSB - PDS Biotechnology Corp

QQQ $ 481.55 $ 0.43 (0.09 %)

DIA $ 408.83 $ -0.40 (-0.1 %)

SPY $ 560.09 $ 0.16 (0.03 %)

TLT $ 98.82 $ 0.14 (0.14 %)

GLD $ 231.98 $ 0.32 (0.14 %)

Previous Close

$ 3.455

Open

$ 3.44

Bid

$ 3.41 x 210

Ask

-- x --

Day's Range

$ 3.36 - $ 3.49

52 Week Range

$ 2.53 - $ 6.85

Volume

319,987

Average Volume

Market Cap

126.78M

Beta (5Y Monthly)

$ 1.75

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-13-2024	06-30-2024	10-Q
2	05-15-2024	03-31-2024	10-Q
3	03-28-2024	12-31-2023	10-K
4	11-14-2023	09-30-2023	10-Q
5	08-14-2023	06-30-2023	10-Q
6	05-15-2023	03-31-2023	10-Q
7	03-28-2023	12-31-2022	10-K
8	11-14-2022	09-30-2022	10-Q
9	08-08-2022	06-30-2022	10-Q
10	05-11-2022	03-31-2022	10-Q
11	03-31-2022	12-31-2021	10-K
12	11-10-2021	09-30-2021	10-Q
13	08-12-2021	06-30-2021	10-Q
14	05-13-2021	03-31-2021	10-Q
15	03-18-2021	12-31-2020	10-K
16	11-13-2020	09-30-2020	10-Q
17	08-13-2020	06-30-2020	10-Q
18	05-13-2020	03-31-2020	10-Q
19	03-27-2020	12-31-2019	10-K
20	11-07-2019	09-30-2019	10-Q
21	08-01-2019	06-30-2019	10-Q
22	05-14-2019	03-31-2019	10-Q
23	02-21-2019	12-31-2018	10-K
24	11-01-2018	09-30-2018	10-Q
25	08-01-2018	06-30-2018	10-Q
26	05-01-2018	03-31-2018	10-Q
27	03-01-2018	12-31-2017	10-K
28	11-01-2017	09-30-2017	10-Q
29	08-01-2017	06-30-2017	10-Q
30	05-03-2017	03-31-2017	10-Q
31	03-02-2017	12-31-2016	10-K
32	11-01-2016	09-30-2016	10-Q
33	08-03-2016	06-30-2016	10-Q
34	05-03-2016	03-31-2016	10-Q
35	03-08-2016	12-31-2015	10-K
36	11-06-2015	09-30-2015	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Alliance Global Partners Maintains Buy on ...
08/20/2024 16:08:22

Alliance Global Partners maintains PDS Biotechnology (NASDAQ:PDSB) with a Buy and raises the price target from $5 to $7.

PDS Biotechnology Entered Amended Sales Ag...
08/13/2024 21:18:55

-424B5

PDS Biotechnology Q2 EPS $(0.23) Beats $(0...
08/13/2024 12:13:02

PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0...

PDS Biotech Announces Updated Data From Th...
08/08/2024 12:22:19

PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy compan...

HC Wainwright & Co. Reiterates Buy on PDS ...
08/01/2024 20:11:42

HC Wainwright & Co. analyst Joseph Pantginis reiterates PDS Biotechnology (NASDAQ:PDSB) with a Buy and maintains $21 pri...

PDS Biotech Aligns With FDA On Phase 3 Tri...
08/01/2024 11:51:28

Company to initiate Phase 3 VERSATILE-003 trial in Q4 2024 Conference Call Today at 8:00 a.m. Eastern TimePRINCETON, N.J., Aug....

HC Wainwright & Co. Reiterates Buy on PDS ...
06/12/2024 17:33:23

HC Wainwright & Co. analyst Joseph Pantginis reiterates PDS Biotechnology (NASDAQ:PDSB) with a Buy and maintains $21 pri...

B. Riley Securities Maintains Buy on PDS B...
06/12/2024 14:15:00

B. Riley Securities analyst Kalpit Patel maintains PDS Biotechnology (NASDAQ:PDSB) with a Buy and lowers the price target fr...

PDS Biotech Shares Data Update From Ongoin...
06/12/2024 12:06:32

Majority of patients continue to be followed for survival with multiple patients approaching 3 years Median Overall Survival (m...

'PDS Biotech's Survival Benefit Is Absurdl...
05/16/2024 15:03:40

https://www.statnews.com/2024/05/16/pds-biotech-survival-benefit/ This is the online edition of Adam's Biotech Scorecard, a...

HC Wainwright & Co. Reiterates Buy on PDS ...
05/15/2024 14:24:17

HC Wainwright & Co. analyst Joseph Pantginis reiterates PDS Biotechnology (NASDAQ:PDSB) with a Buy and maintains $21 pri...

PDS Biotechnology Q1 2024 GAAP EPS $(0.30)...
05/15/2024 12:04:37

PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0...

PDS Biotech's VERSATILE-002 Phase 2 Clinic...
05/09/2024 22:09:29

HC Wainwright & Co. Reiterates Buy on PDS ...
05/09/2024 19:35:07

HC Wainwright & Co. analyst Joseph Pantginis reiterates PDS Biotechnology (NASDAQ:PDSB) with a Buy and maintains $21 pri...

Cantor Fitzgerald Reiterates Overweight on...
05/09/2024 15:12:14

Cantor Fitzgerald analyst Louise Chen reiterates PDS Biotechnology (NASDAQ:PDSB) with a Overweight.

PDS Biotech Appoints Stephan Toutain As Ch...
05/02/2024 12:06:32

PDS Biotech To Event To Discuss Positive,...
04/23/2024 12:01:45

Company to Host Key Opinion Leader Event on May 8 at 1:30pm ET to Discuss Updated Results of VERSATILE-002, Unmet Treatment Nee...

B. Riley Securities Reiterates Buy on PDS ...
03/28/2024 16:00:13

B. Riley Securities analyst Kalpit Patel reiterates PDS Biotechnology (NASDAQ:PDSB) with a Buy and lowers the price target f...

12-health-care-stocks-moving-in-wednesdays-intraday-session

12 Health Care Stocks Moving In Wednesday'...
03/27/2024 16:31:07

HC Wainwright & Co. Maintains Buy on PDS B...
03/27/2024 14:28:41

HC Wainwright & Co. analyst Joseph Pantginis maintains PDS Biotechnology (NASDAQ:PDSB) with a Buy and maintains $21 pric...